Sentence examples for molecular screening in from inspiring English sources

This paradigm is challenged by the need to perform widespread molecular screening in certified laboratories, with results available to clinicians within reasonable timeframe.

To investigate prevalence and clinical characteristics of klassevirus in South Korea, we performed molecular screening in fecal and nasopharyngeal samples from hospitalized children with gastroenteritis.

The first step in MUTYH molecular screening in Caucasian patients is usually represented by the search for the two common mutations.

Additional studies are needed to evaluate the feasibility, clinical utility, and cost-effectiveness of molecular screening in breast cancer using high-throughput next-generation sequencing technology.

This clinical experience suggests that (i) patients with BRAF V600DK601del -mutation-positive melanoma can be treated successfully with the oral BRAF inhibitor vemurafenib and (ii) molecular screening in this context should encompass rare and complex mutations.

This policy is already identifying further mutation-positive families (not included in the present report) among those who would not currently be eligible for full-scale molecular screening in our diagnostic laboratories (Haites et al, 2000).

We describe the derivation and internal validation of a scoring system able to predict the probability of nasal MRSA carriage and the expected PPV of a molecular screening test in admissions to a European tertiary referral center with low prevalence.

This article provides an overview of the recent molecular insights in breast cancer, including potentially actionable somatic alterations, the technological platforms currently available in a clinical diagnostics setting to detect these alterations, and ongoing institutional or regional molecular screening programs in advanced breast cancer.

To date, bacterial chitinase genes have been identified, by conventional molecular screening approaches, in bacterial isolates or uncultured bacteria within both aquatic and soil environments (for example, Hobel et al. 2005; Ikeda et al. 2007; LeCleir et al. 2004; Metcalfe et al. 2002; Ramaiah et al. 2000; Terahara et al. 2009; Uchiyama and Watanabe 2006).

Because CHD is generally the first presenting symptom in such patients, molecular screening for 22q11.2 in CHD patients is important in the evaluation of associated noncardiac features [ 17].

6, 24 The advantages and disadvantages of the methods currently used for molecular screening and diagnosis in HCM are shown in Table 2.